1. |
Cho EH, Dai Y. SIRT1 controls cell proliferation by regulating contact inhibition. Biochem Biophys Res Commun, 2016, 478(2): 868-872.
|
2. |
Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol, 2007, 17(1): 2-9.
|
3. |
Meng X, Chen X, Lu P, et al. miR-202 promotes cell apoptosis in esophageal squamous cell carcinoma by targeting HSF2. Oncol Res, 2017, 25(2): 215-223.
|
4. |
He Z, Yi J, Jin L, et al. Overexpression of Sirtuin-1 is associated with poor clinical outcome in esophageal squamous cell carcinoma. Tumour Biol, 2016, 37(6): 7139-7148.
|
5. |
Ye Z, Fang J, Dai S, et al. MicroRNA-34a induces a senescence-like change via the down-regulation of SIRT1 and up-regulation of p53 protein in human esophageal squamous cancer cells with a wild-type p53 gene background. Cancer Lett, 2016, 370(2): 216-221.
|
6. |
Shen L, Shan YS, Hu HM, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol, 2013, 14(12): e535-e547.
|
7. |
Qiu G, Li X, Che X, et al. SIRT1 is a regulator of autophagy: Implications in gastric cancer progression and treatment. FEBS Lett, 2015, 589(16): 2034-2042.
|
8. |
Kim SY, Ko YS, Park J, et al. Forkhead transcription factor FOXO1 inhibits angiogenesis in gastric cancer in relation to SIRT1. Cancer Res Treat, 2016, 48(1): 345-354.
|
9. |
Li J, Dong G, Wang B, et al. miR-543 promotes gastric cancer cell proliferation by targeting SIRT1. Biochem Biophys Res Commun, 2016, 469(1): 15-21.
|
10. |
Wang J, Xue X, Hong H, et al. Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9. Oncotarget, 2017, 8(1): 574-582.
|
11. |
Su J, Wu S, Tang W, et al. Reduced SLC27A2 induces cisplatin resistance in lung cancer stem cells by negatively regulating Bmi1-ABCG2 signaling. MolCarcinog, 2016, 55(11): 1822-1832.
|
12. |
Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer, 2005, 5(4): 311-321.
|
13. |
Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell, 2012, 21(3): 283-296.
|
14. |
Zhang L, Guo X, Zhang D, et al. Upregulated miR-132 in Lgr5+ gastric cancer stem cell-like cells contributes to cisplatin-resistance via SIRT1/CREB/ABCG2 signaling pathway. Mol Carcinog, 2017, 56(9): 2022-2034.
|
15. |
Azer SA. Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development. Eur J Gastroenterol Hepatol, 2013, 25(3): 271-281.
|
16. |
Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin, 2014, 64(1): 9-29.
|
17. |
Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin, 2017, 67(3): 177-193.
|
18. |
Fu Z, Shrubsole MJ, Smalley WE, et al. Association of meat intake and meat-derived mutagen exposure with the risk of colorectal polyps by histologic type. Cancer Prev Res (Phila), 2011, 4(10): 1686-1697.
|
19. |
Piepoli A, Tavano F, Copetti M, et al. Mirna expression profiles identify drivers in colorectal and pancreatic cancers. PLoS One, 2012, 7(3): e33663.
|
20. |
Chueca E, Lanas A, Piazuelo E. Role of gastrin-peptides in Barrett’s and colorectal carcinogenesis. World J Gastroenterol, 2012, 18(45): 6560-6570.
|
21. |
Yu DF, Jiang SJ, Pan ZP, et al. Expression and clinical significance of Sirt1 in colorectal cancer. Oncol Lett, 2016, 11(2): 1167-1172.
|
22. |
Shen ZL, Wang B, Jiang KW, et al. Down regulation of miR-199b is associated with distant metastasis in colorectal cancer via activation of SIRT1 and inhibition of CREB/KISS1 signaling. Oncotarget, 2016, 7(23): 35092-35105.
|
23. |
Cheng F, Su L, Yao C, et al. SIRT1 promotes epithelial-mesenchymal transition and metastasis in colorectal cancer by regulating Fra-1 expression. Cancer Lett, 2016, 375(2): 274-283.
|
24. |
Carew JS, Nawrocki ST, Cleveland JL. Modulating autophagy for therapeutic benefit. Autophagy, 2007, 3(5): 464-467.
|
25. |
Song J, Qu Z, Guo X, et al. Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells. Autophagy, 2009, 5(8): 1131-1144.
|
26. |
Xiong H, Ni Z, He J, et al. LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene, 2017, 36(25): 3528-3540.
|
27. |
Ling S, Li J, Shan Q, et al. USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway. MolOncol, 2017, 11(6): 682-695.
|
28. |
Jiang H, Zhang X, Tao Y, et al. Prognostic and clinicopathologic significance of SIRT1 expression in hepatocellular carcinoma. Oncotarget, 2016, 8(32): 52357-52365.
|
29. |
Tian Z, Jiang H, Liu Y, et al. MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1. Exp Cell Res, 2016, 343(2): 135-147.
|
30. |
Jiang G, Wen L, Zheng H, et al. miR-204-5p targeting SIRT1 regulates hepatocellular carcinoma progression. Cell Biochem Funct, 2016, 34(7): 505-510.
|
31. |
Hidalgo M. Pancreatic cancer. N Engl J Med, 2010, 362(17): 1605-1617.
|
32. |
Shi X, Liu R, Basolo F, et al. Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J Clin Endocrinol Metab, 2016, 101(1): 264-274.
|
33. |
Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res, 2014, 74(11): 2913-2921.
|
34. |
Jin J, Chu Z, Ma P, et al. SIRT1 promotes the proliferation and metastasis of human pancreatic cancer cells. Tumour Biol, 2017, 39(3): 1010428317691180.
|
35. |
Tian S, Guo X, Yu C, et al. miR-138-5p suppresses autophagy in pancreatic cancer by targeting SIRT1. Oncotarget, 2017, 8(7): 11071-11082.
|
36. |
Liu Y, Li X, Zhu S, et al. Ectopic expression of miR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc. Gene Ther, 2015, 22(9): 729-738.
|
37. |
Chini CC, Espindola-Netto JM, Mondal G, et al. SIRT1-activating compounds (STAC) negatively regulate pancreatic cancer cell growth and viability through a SIRT1 lysosomal-dependent pathway. Clin Cancer Res, 2016, 22(10): 2496-2507.
|
38. |
Kim JE, Chen J, Lou Z. DBC1 is a negative regulator of SIRT1. Nature, 2008, 451(7178): 583-586.
|
39. |
Fang Y, Nicholl MB. Sirtuin 1 in malignant transformation: friend or foe? Cancer Lett, 2011, 306(1): 10-14.
|
40. |
Liu T, Liu PY, Marshall GM. The critical role of the class Ⅲ histone deacetylase SIRT1 in cancer. Cancer Res, 2009, 69(5): 1702-1705.
|